FULCRUM THERAPEUTICS, INC. Payments to Acquire Marketable Securities
FULCRUM THERAPEUTICS, INC. (FULC) reported Payments to Acquire Marketable Securities of $179.55 million for the 6-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2026-06-30 was $24.22M, a 68.30% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2026-03-31 was $155.34M, a 157.19% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2025-12-31 was $26.14M, a 22.08% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2025-09-30 was $17.29M, a 54.65% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2023 was $194.89M, a 28.94% increase from fiscal 2022.
- FULCRUM THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2022 was $151.15M, a 30.10% decline from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2021 was $216.23M, a 74.00% increase from fiscal 2020.
- FULCRUM THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2020 was $124.27M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.22M derived: S-4 6 month − 10-Q 3 month · filed 2026-09-02 | $179.55M S-4 · filed 2026-09-02 | $205.69M derived: sum of 3 quarters · filed 2026-09-02 | $222.98M derived: sum of 4 quarters · filed 2026-09-02 |
| 2026-03-31 | $155.34M 10-Q · filed 2026-04-27 | $181.47M derived: sum of 2 quarters · filed 2026-09-02 | $198.77M derived: sum of 3 quarters · filed 2026-09-02 | $275.16M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-12-31 | $26.14M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $43.43M derived: sum of 2 quarters · filed 2026-09-02 | $119.82M derived: sum of 3 quarters · filed 2026-09-02 | $180.22M S-4 · filed 2026-09-02 |
| 2025-09-30 | $17.29M derived: 10-Q 9 month − S-4 6 month · filed 2025-10-29 | $93.69M derived: sum of 2 quarters · filed 2026-09-02 | $154.08M 10-Q · filed 2025-10-29 | $175.49M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-06-30 | $76.39M derived: S-4 6 month − 10-Q 3 month · filed 2026-09-02 | $136.79M S-4 · filed 2026-09-02 | $158.20M derived: sum of 3 quarters · filed 2026-09-02 | $196.33M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-03-31 | $60.40M 10-Q · filed 2026-04-27 | $81.81M derived: sum of 2 quarters · filed 2026-09-02 | $119.94M derived: sum of 3 quarters · filed 2026-09-02 | $183.18M derived: sum of 4 quarters · filed 2026-09-02 |
| 2024-12-31 | $21.41M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $59.54M derived: sum of 2 quarters · filed 2026-09-02 | $122.78M derived: sum of 3 quarters · filed 2026-09-02 | $178.59M S-4 · filed 2026-09-02 |
| 2024-09-30 | $38.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $101.37M derived: sum of 2 quarters · filed 2025-10-29 | $157.19M 10-Q · filed 2025-10-29 | $182.26M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-06-30 | $63.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $119.05M 10-Q · filed 2025-07-29 | $144.13M derived: sum of 3 quarters · filed 2025-07-29 | $170.11M derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | $55.82M 10-Q · filed 2025-05-01 | $80.89M derived: sum of 2 quarters · filed 2025-05-01 | $106.88M derived: sum of 3 quarters · filed 2025-05-01 | $124.20M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $25.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $51.06M derived: sum of 2 quarters · filed 2025-02-25 | $68.39M derived: sum of 3 quarters · filed 2025-02-25 | $194.89M 10-K · filed 2025-02-25 |
| 2023-09-30 | $25.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $43.31M derived: sum of 2 quarters · filed 2024-11-13 | $169.82M 10-Q · filed 2024-11-13 | $253.11M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $17.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $143.83M 10-Q · filed 2024-07-31 | $227.12M derived: sum of 3 quarters · filed 2024-07-31 | $279.82M derived: sum of 4 quarters · filed 2024-07-31 |
| 2023-03-31 | $126.50M 10-Q · filed 2024-05-13 | $209.79M derived: sum of 2 quarters · filed 2024-05-13 | $262.49M derived: sum of 3 quarters · filed 2024-05-13 | $272.67M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $83.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $135.99M derived: sum of 2 quarters · filed 2024-02-27 | $146.16M derived: sum of 3 quarters · filed 2024-02-27 | $151.15M 10-K · filed 2024-02-27 |
| 2022-09-30 | $52.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $62.87M derived: sum of 2 quarters · filed 2023-11-07 | $67.86M 10-Q · filed 2023-11-07 | $102.75M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $10.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $15.17M 10-Q · filed 2023-08-03 | $50.05M derived: sum of 3 quarters · filed 2023-08-03 | $179.62M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $4.99M 10-Q · filed 2023-05-15 | $39.88M derived: sum of 2 quarters · filed 2023-06-26 | $169.44M derived: sum of 3 quarters · filed 2023-06-26 | $218.23M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-12-31 | $34.88M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $164.45M derived: sum of 2 quarters · filed 2023-06-26 | $213.24M derived: sum of 3 quarters · filed 2023-06-26 | $216.23M 10-K/A · filed 2023-06-26 |
| 2021-09-30 | $129.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $178.35M derived: sum of 2 quarters · filed 2022-11-08 | $181.35M 10-Q · filed 2022-11-08 | $224.35M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-06-30 | $48.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $51.78M 10-Q · filed 2022-08-11 | $94.78M derived: sum of 3 quarters · filed 2023-06-26 | $103.40M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-03-31 | $3.00M 10-Q · filed 2022-05-09 | $46.00M derived: sum of 2 quarters · filed 2023-06-26 | $54.61M derived: sum of 3 quarters · filed 2023-06-26 | $71.43M derived: sum of 4 quarters · filed 2023-06-26 |
| 2020-12-31 | $43.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $51.62M derived: sum of 2 quarters · filed 2023-06-26 | $68.43M derived: sum of 3 quarters · filed 2023-06-26 | $124.27M 10-K/A · filed 2023-06-26 |
| 2020-09-30 | $8.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $25.43M derived: sum of 2 quarters · filed 2021-11-04 | $81.27M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $16.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $72.65M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $55.84M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |